Single Cell Genomics (SCG) Report 2013: Market Size, Segmentation, Growth, Competition and Trends

  • ID: 2643657
  • Report
  • Region: Global
  • 100 Pages
  • DeciBio
1 of 5
Single cell genomics (SCG) is a fast growing, emerging approach in which genomic technologies (i.e., that assess nucleic acids such as DNA or RNA) are applied at the level of single cells, rather than at the level of an entire cell population. The first edition of this report reviews the market size, segmentation, growth and trends of the SCG market.

We assess the SCG market across 7 segments and 32 sub-segments:

- Customer (academia, biopharma, applied markets, clinical)
- Workflow step (cell isolation, sample preparation, genomic analysis)
- Analytical technology (PCR, qPCR, microarray, next-generation-sequencing, other)
- Field-of-study (oncology, basic cell biology, stem cell biology, microbiology, neurology, immunology, other)
- Application (genomic variation, subpopulation characterization, circulating tumor cells, cell differentiation / reprogramming, method, other)
- Product type (instruments, reagents)
- Geography (U.S., Europe, Japan, Asia-Pacific, ROW)

For each of these segments, we provide an estimated market size and growth from 2009 to 2018, as well as key growth drivers and moderators. In addition, we review key factors driving future growth including 1) accelerating interest among scientists given a number of applications that SCG can enable, 2) launch of new platforms that streamline the historically laborious and low throughput workflow, 3) development of new protocols and reagents optimized to improve the amplification of DNA/RNA from single cells for downstream analysis and 5) adoption of SCG by new customers segments, most notably clinical laboratories.

On the other hand, we discuss several key factors moderating growth including 1) remaining workflow challenges, including isolating cells from tissue and recovering DNA / RNA at a high yield, amplifying DNA / RNA with limited bias and downstream computational analysis, 2) continued funding pressures for academic customers (currently representing the majority of the market) particularly in the U.S. and Europe. Special analysis conducted in this report includes the analysis and categorization of ~300 SCG publications published since 2007.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
1. TABLE OF CONTENTS
AUTHORS
ABSTRACT

2. EXECUTIVE SUMMARY

3. MARKET REPORT INTRODUCTION
Context
Market Sizing Methodology

4. GENOMICS AND SINGLE CELL GENOMICS OVERVIEW
Genomics Market Overview
Single Cell Genomics (SCG) Overview
SCG Opportunities for Market Participants

5. SINGLE CELL GENOMICS PUBLICATION ANALYSIS
Methodology
SCG Publications by Field-of-Study
SCG Publications by Application
SCG Publications by Analytical Technology
SCG Publications by Geography

6. SINGLE CELL GENOMICS MARKET SIZE
Market Size and Growth - Overall
Market Size and Growth by Customer
Market Size and Growth by Workflow Step
Market Size and Growth by Analytical Technology
Market Size and Growth by Field-of-Study
Market Size and Growth by Application
Market Size and Growth by Product Type
Market Size and Growth by Geography

7. SINGLE CELL GENOMICS COMPETITIVE ANALYSIS
Competitive Overview
Company Spotlight: Fluidigm
SCG Product Highlights: Nanostring
SCG Product Highlights: NuGEN
SCG Product Highlights: BD Biosciences
SCG Product Highlights: Qiagen

8. APPENDIX
More about DeciBio
Related DeciBio Reports
Publication Analysis
Competitor Profiles
Table of Exhibits
Abbreviations
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
David Cavanaugh is a partner at DeciBio, with over 15 years of combined experience in life science business consulting and life science research and development. David has extensive experience publishing on the research tools and clinical diagnostic markets and advising leaders in these markets on various business issues. Prior to DeciBio, David worked for six years at L.E.K. Consulting, most recently as a Senior Manager where he managed multiple ongoing life science engagements at a time. Prior to that, David worked for seven years as a computational biologist at leading organizations, including Genentech and GlaxoSmithKline. David earned his M.B.A from the Kellogg School of Management at Northwestern University with a focus in biotechnology, healthcare management, and international business strategy. David received his B.S. in Chemical Engineering from the University of Virginia.

Stephane Budel is a partner at DeciBio with over 13 years of combined experience in life science business consulting, entrepreneurship, and academic research. Stephane specializes in the analysis of private to mid-cap companies with established to emerging technologies in the life science research tools and molecular diagnostics spaces. He has supported life science research tools clients facing a broad range of challenging business development issues, including R&D prioritization and evaluation of disruptive technologies. Stephane is a market expert who specializes in the cutting edge of these markets, with a deep understanding of the technical and business potential of innovative technologies such as qPCR, and NGS. Prior to DeciBio, Stephane earned his Ph.D. from Yale University for his research on the molecular mechanisms of spinal cord injury and schizophrenia. A central part of his research relied on genomics technologies, and included collaboration with 454 Life Sciences.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll